Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8393830 | 0.92 | HTT (0.63) | HTTALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL8395012 | 0.92 | HTT (0.69) | HTTALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL12820039 | 0.91 | HTT (0.49) | HTTALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL21161446 | 0.91 | HTT (0.49) | HTTALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL15715057 | 0.91 | MAPK1 (0.57) | HTTALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL15014622 | 0.91 | MAPK1 (0.57) | HTTALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL30423567 | 0.90 | HTT (0.72) | HTTALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL8396994 | 0.90 | HTT (0.72) | HTTALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL8392442 | 0.90 | HTT (0.72) | HTTALDH1A1MAPTKMT2ASMN1; SMN2 | |
| Bicarbonate SCHEMBL15226014 | 0.87 | HTT (0.68) | HTTALDH1A1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476445-B2 | Process for production of piperidine derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100137605-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7678915-B2 | Process for production of piperidine derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070010677-A1 | Process for production of piperidine derivatives | AMR TECHNOLOGY, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20050209279-A1 | Process for production of piperidine derivatives | AMR TECHNOLOGY, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| US-6919458-B2 | Process for production of piperidine derivatives | AMR TECHNOLOGY, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-0868182-B1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RES INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030028029-A1 | Process for production of piperidine derivatives | BARCLAYS BANK PLC, AS THE COLLATERAL AGENT | 2003-02-06 | — | — | US | disclosed |
| US-6458958-B1 | PROCESS OF PREPARING A PIPERIDINE DERIVATIVE COMPOUND OF THE FORMULA: ACYLATING AN .ALPHA.,.ALPHA.-DISUBSTITUTED-METHYLBENZENE DERIVATIVE HAVING THE FORMULA: | ALBANY MOLECULAR RESEARCH, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6444824-B1 | ANTISEROTONINE AGENTS; SIDE EFFECT REDUCTION | ALBANY MOLECULAR RESEARCH, INC. | 2002-09-03 | — | — | US | disclosed |
| US-6153754-A | Process for production of piperidine derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0868182-A4 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RES INC (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| EP-0868182-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 1998-10-07 | — | — | EP | disclosed |
| WO-1997023213-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 1997-07-03 | — | — | WO | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137605-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | HPD, PTMA, HAAO | HTT 999/4885ALDH1A1 20/4885MAPT 3355/4885 |
| US-20050209279-A1 | Process for production of piperidine derivatives | NR5A2, NR4A1, NR4A2 | HTT 3976/4885ALDH1A1 1917/4885MAPT 4710/4885 |
| US-20070010677-A1 | Process for production of piperidine derivatives | NR4A1, NR5A2, NR4A2 | HTT 4027/4885ALDH1A1 1155/4885MAPT 4624/4885 |
| US-20030028029-A1 | Process for production of piperidine derivatives | NR4A1, RCOR1, CBR1 | HTT 3427/4885ALDH1A1 1129/4885MAPT 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.